Literature DB >> 26122641

mTOR regulates TLR-induced c-fos and Th1 responses to HBV and HCV vaccines.

Li He1, Aiping Zang, Min Du, Dapeng Ma, Chuanping Yuan, Chun Zhou, Jing Mu, Huanjing Shi, Dapeng Li, Xulin Huang, Qiang Deng, Jianhua Xiao, Huimin Yan, Lijian Hui, Ke Lan, Sidong Xiong, Xiaoxia Li, Zhong Huang, Hui Xiao.   

Abstract

Although IL-12 plays a critical role in priming Th1 and cytotoxic T lymphocyte (CTL) responses, Toll-like receptor (TLR) signaling only induces low amounts of IL-12 in dendritic cells and macrophages, implying the existence of stringent regulatory mechanisms. In this study, we sought to uncover the mechanisms underlying TLR-induced IL-12 expression and the Th1 response. By systemic screening, we identified a number of protein kinases involved in the regulation of TLRinduced IL-12 expression. In particular, PI3K, ERK, and mTOR play critical roles in the TLR-induced Th1 response by regulating IL-12 and IL-10 production in innate immune cells. Moreover, we identified c-fos as a key molecule that mediates mTOR-regulated IL-12 and IL-10 expression in TLR signaling. Mechanistically, mTOR plays a crucial role in c-fos expression, thereby modulating NFκB binding to promoters of IL-12 and IL-10. By controlling the expression of a special innate gene program, mTOR can specifically regulate the TLR-induced T cell response in vivo. Furthermore, blockade of mTOR by rapamycin efficiently boosted TLR-induced antigen-specific T and B cell responses to HBV and HCV vaccines. Taken together, these results reveal a novel mechanism through which mTOR regulates TLR-induced IL-12 and IL-10 production, contributing new insights for strategies to improve vaccine efficacy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26122641      PMCID: PMC8200861          DOI: 10.1007/s12250-015-3606-3

Source DB:  PubMed          Journal:  Virol Sin        ISSN: 1995-820X            Impact factor:   4.327


  37 in total

Review 1.  Cooperation of Toll-like receptor signals in innate immune defence.

Authors:  Giorgio Trinchieri; Alan Sher
Journal:  Nat Rev Immunol       Date:  2007-03       Impact factor: 53.106

2.  Comprehensive analyses of CD8+ T cell responses during longitudinal study of acute human hepatitis C.

Authors:  Andrea L Cox; Timothy Mosbruger; Georg M Lauer; Drew Pardoll; David L Thomas; Stuart C Ray
Journal:  Hepatology       Date:  2005-07       Impact factor: 17.425

3.  Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo.

Authors:  Tobias Warger; Philipp Osterloh; Gerd Rechtsteiner; Melanie Fassbender; Valeska Heib; Beate Schmid; Edgar Schmitt; Hansjörg Schild; Markus P Radsak
Journal:  Blood       Date:  2006-03-14       Impact factor: 22.113

Review 4.  Interleukin-10 and the interleukin-10 receptor.

Authors:  K W Moore; R de Waal Malefyt; R L Coffman; A O'Garra
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

Review 5.  New hepatitis B vaccine formulated with an improved adjuvant system.

Authors:  Michael Kundi
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

6.  The role of tuberous sclerosis complex 1 in regulating innate immunity.

Authors:  Hongjie Pan; Thomas F O'Brien; Ping Zhang; Xiao-Ping Zhong
Journal:  J Immunol       Date:  2012-03-12       Impact factor: 5.422

7.  Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients.

Authors:  Norella Kong Chiew Tong; Jiri Beran; Swee Ann Kee; Jose Luis Miguel; Carmen Sánchez; Jose Maria Bayas; A Vilella; J R de Juanes; P Arrazola; Francisco Calbo-Torrecillas; Eduardo López de Novales; Virginie Hamtiaux; Marc Lievens; Michel Stoffel
Journal:  Kidney Int       Date:  2005-11       Impact factor: 10.612

8.  Mammalian target of rapamycin (mTOR) orchestrates the defense program of innate immune cells.

Authors:  Frank Schmitz; Antje Heit; Stefan Dreher; Katharina Eisenächer; Jörg Mages; Tobias Haas; Anne Krug; Klaus-Peter Janssen; Carsten J Kirschning; Hermann Wagner
Journal:  Eur J Immunol       Date:  2008-11       Impact factor: 5.532

Review 9.  Improving vaccine delivery using novel adjuvant systems.

Authors:  Michael E Pichichero
Journal:  Hum Vaccin       Date:  2008-02-15

Review 10.  Regulation of interleukin-12/interleukin-23 production and the T-helper 17 response in humans.

Authors:  Lyudmila Lyakh; Giorgio Trinchieri; Lisa Provezza; Giuseppe Carra; Franca Gerosa
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

View more
  9 in total

1.  Gut epithelial TSC1/mTOR controls RIPK3-dependent necroptosis in intestinal inflammation and cancer.

Authors:  Yadong Xie; Yifan Zhao; Lei Shi; Wei Li; Kun Chen; Min Li; Xia Chen; Haiwei Zhang; Tiantian Li; Yu Matsuzawa-Ishimoto; Xiaomin Yao; Dianhui Shao; Zunfu Ke; Jian Li; Yan Chen; Xiaoming Zhang; Jun Cui; Shuzhong Cui; Qibin Leng; Ken Cadwell; Xiaoxia Li; Hong Wei; Haibing Zhang; Huabin Li; Hui Xiao
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 2.  Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells.

Authors:  Xiaojing Ma; Wenjun Yan; Hua Zheng; Qinglin Du; Lixing Zhang; Yi Ban; Na Li; Fang Wei
Journal:  F1000Res       Date:  2015-12-17

3.  Microparticles produced by human papillomavirus type 16 E7-expressing cells impair antigen presenting cell function and the cytotoxic T cell response.

Authors:  J Zhang; C Burn; K Young; M Wilson; K Ly; M Budhwani; A Tschirley; A Braithwaite; M Baird; M Hibma
Journal:  Sci Rep       Date:  2018-02-05       Impact factor: 4.379

4.  Epigenetic regulator CXXC5 recruits DNA demethylase Tet2 to regulate TLR7/9-elicited IFN response in pDCs.

Authors:  Shixin Ma; Xiaoling Wan; Zihou Deng; Lei Shi; Congfang Hao; Zhenyuan Zhou; Chun Zhou; Yiyuan Fang; Jinghua Liu; Jing Yang; Xia Chen; Tiantian Li; Aiping Zang; Shigang Yin; Bin Li; Joel Plumas; Laurence Chaperot; Xiaoming Zhang; Guoliang Xu; Lubin Jiang; Nan Shen; Sidong Xiong; Xiaoming Gao; Yan Zhang; Hui Xiao
Journal:  J Exp Med       Date:  2017-04-17       Impact factor: 14.307

5.  mTOR inhibitors improve both humoral and cellular response to SARS-CoV-2 messenger RNA BNT16b2 vaccine in kidney transplant recipients.

Authors:  Giuseppe S Netti; Barbara Infante; Dario Troise; Silvia Mercuri; Maddalena Panico; Federica Spadaccino; Valeria Catalano; Margherita Gigante; Simona Simone; Paola Pontrelli; Loreto Gesualdo; Elena Ranieri; Giuseppe Castellano; Giovanni Stallone
Journal:  Am J Transplant       Date:  2022-01-28       Impact factor: 9.369

Review 6.  mTOR-Mediated Regulation of Dendritic Cell Differentiation and Function.

Authors:  Nyamdelger Sukhbaatar; Markus Hengstschläger; Thomas Weichhart
Journal:  Trends Immunol       Date:  2016-09-07       Impact factor: 16.687

Review 7.  Metabolic reprogramming during hepatitis B disease progression offers novel diagnostic and therapeutic opportunities.

Authors:  Jesse Jr Masson; Hugh Ww Billings; Clovis S Palmer
Journal:  Antivir Chem Chemother       Date:  2017-08

8.  Surface Immunogenic Protein of Streptococcus Group B is an Agonist of Toll-Like Receptors 2 and 4 and a Potential Immune Adjuvant.

Authors:  Diego A Diaz-Dinamarca; Ricardo A Manzo; Daniel A Soto; María José Avendaño-Valenzuela; Diego N Bastias; Paulina I Soto; Daniel F Escobar; Valeria Vasquez-Saez; Flavio Carrión; Magdalena S Pizarro-Ortega; Christian A M Wilson; Julio Berrios; Alexis M Kalergis; Abel E Vasquez
Journal:  Vaccines (Basel)       Date:  2020-01-16

Review 9.  mTOR Signaling: The Interface Linking Cellular Metabolism and Hepatitis B Virus Replication.

Authors:  Xueyu Wang; Zhiqiang Wei; Yongfang Jiang; Zhongji Meng; Mengji Lu
Journal:  Virol Sin       Date:  2021-09-28       Impact factor: 4.327

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.